Causes of death among patients with cutaneous melanoma: a US population-based study

Abstract

Research on mortality outcomes and non-cancer-related causes of death in patients with cutaneous melanoma (CM) remains limited. This study aimed to identify the prevalence of non-cancer-related deaths following CM diagnosis. The data of 224,624 patients diagnosed with malignant CM in the United States between 2000 and 2019 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. We stratified our cohort based on their melanoma stage at diagnosis and further calculated standardized mortality ratios (SMRs) for each cause of death, comparing their relative risk to that of the general US population. The total number of fatalities among melanoma patients was 60,110, representing 26.8% of the total cases. The percentage of deaths is directly proportional to the disease stage, reaching 80% in distant melanoma. The highest fatalities among the localized melanoma group (25,332; 60.5%) occurred from non-cancer causes, followed by melanoma-attributable deaths (10,817; 25.8%). Conversely, melanoma is the leading cause of death in regional and distant melanoma cohorts. Cardiovascular and cerebrovascular diseases were the most prevalent non-cancer causes of death among the three disease-stage cohorts. Compared to the general population, we did not observe an increased risk of death due to non-cancer causes in the localized CM cohort, while patients diagnosed with regional and distant CMs had a statistically significant higher risk of death from all the reported major causes of death.

Elesclomol Loaded Copper Oxide Nanoplatform Triggers Cuproptosis to Enhance Antitumor Immunotherapy

“…[ 1 , 2 ] Melanoma is the fifth most common cancer worldwide and the leading cause of skin cancer‐related death. [ 3 , 4 ] This disease frequently metastasizes to and can spread to distant organs such as the brain, lung, liver, and bone through lymph nodes and blood vessels. [ 5 , 6 ] Currently, immune checkpoint inhibitors (ICIs), represented by programmed cell death‐1 (PD‐1) antibodies, have shown outstanding therapeutic efficacy for patients with immunogenic melanoma in the clinic.…”

Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis

“…The insufficient evidence for screening as a secondary prevention for the early detection of melanoma patients contributes to the disease Cancers 2023, 15, 3754 2 of 16 burden [6,7]. In addition, some patients experience disease progression or are diagnosed with advanced disease, leading to poorer outcomes [8,9].…”